EndoGene.Bio Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
7
EndoGene.Bio General Information
Description
Developer of a biotechnology platform intended to use precision medicine to transform how endometriosis is diagnosed and treated. The company's platform helps to accelerate the diagnosis of endometriosis from months to weeks through a non-invasive endometriosis diagnostic test for improved diagnostics, patient stratification, and drug development using menstrual blood, enabling medical professionals to easily prepare tests based on proprietary epigenetic biomarkers in menstrual blood.
Contact Information
Website
www.endogene.bioCorporate Office
- 3 Boulevard de Srebatopol
- 75001 Paris
- France
Corporate Office
- 3 Boulevard de Srebatopol
- 75001 Paris
- France
EndoGene.Bio Timeline
EndoGene.Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 24-Aug-2026 | Completed | Startup | |||
| 6. Grant | 15-Jun-2026 | Completed | Startup | |||
| 5. Early Stage VC | 01-Feb-2025 | Completed | Startup | |||
| 4. Accelerator/Incubator | 01-Aug-2024 | Completed | Startup | |||
| 3. Accelerator/Incubator | 20-Feb-2022 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
EndoGene.Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EndoGene.Bio Patents
EndoGene.Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3173023-A1 | Diagnostic methods for endometriosis based on epigenetic biomarkers and methods for identifying these biomarkers | Pending | 11-Mar-2025 | ||
| WO-2026190192-A1 | Methods of diagnosis of endometriosis based on epigenetic biomarkers and methods for identification of those biomarkers | Pending | 11-Mar-2025 | ||
| FR-3161348-A1 | Kit for collecting a menstrual blood sample | Pending | 19-Apr-2024 | ||
| AU-2025256348-A1 | Kit for collecting a sample of menstrual blood | Pending | 19-Apr-2024 | ||
| WO-2025219589-A1 | Kit for collecting a sample of menstrual blood | Pending | 19-Apr-2024 | A61F5/4553 |
EndoGene.Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EndoGene.Bio Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DayOne Accelerator | Accelerator/Incubator | |||
| Hello Tomorrow | Accelerator/Incubator | |||
| Frontline Ventures | Venture Capital | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Entrepreneurs First | Venture Capital | Minority |
EndoGene.Bio FAQs
-
When was EndoGene.Bio founded?
EndoGene.Bio was founded in 2022.
-
Where is EndoGene.Bio headquartered?
EndoGene.Bio is headquartered in Paris, France.
-
What is the size of EndoGene.Bio?
EndoGene.Bio has 13 total employees.
-
What industry is EndoGene.Bio in?
EndoGene.Bio’s primary industry is Biotechnology.
-
Is EndoGene.Bio a private or public company?
EndoGene.Bio is a Private company.
-
What is EndoGene.Bio’s current revenue?
The current revenue for EndoGene.Bio is .
-
How much funding has EndoGene.Bio raised over time?
EndoGene.Bio has raised $1.74M.
-
Who are EndoGene.Bio’s investors?
DayOne Accelerator, Hello Tomorrow, Frontline Ventures, Bpifrance, and Entrepreneurs First are 5 of 7 investors who have invested in EndoGene.Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
